Unlock insights for autoimmune therapies
With easily accessible blood samplesDeep immune profiling paired with a robust analysis platform can unlock actionable insights for therapy development. This data is now measurable in peripheral blood through the TokuProfile.
Understanding how a therapy works at a cellular level can improve trial design and accelerate candidates to approval.
Immune monitoring has emerged as an essential tool for the development of autoimmune therapies.
Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases
Candidate Markers for Stratification and Classification in Rheumatoid Arthritis
Cytometry by time of flight identifies distinct signatures in patients with systemic sclerosis, systemic lupus erythematosus and Sjögrens syndrome
Accelerate the Pipeline
- Discovery Mechanism of action
Mechanism of resistance
Rational combinations - Phase I/II ID response characteristics
Novel pathway identification
Rational combinations - Phase III Likelihood for Response
Likelihood for Adverse Events
Novel Pathway Identification – Cancer Example
A TokuProfile™ Can Reveal Unique Insights
Before Teiko.bio
The assumption is that CD8 T-cells need to be targeted directly. However, this leads to therapy failure.
Discovery
Profiling reveals that even though CD8 T-cells appear suppressed, the actual issue is with the Dendritic Cells not being active.
After Teko.bio
Anti CD40 Therapy Activates Dendritic Cells to create therapy success.
